Customize Consent Preferences

We use cookies to help you navigate efficiently and perform certain functions. You will find detailed information about all cookies under each consent category below.

The cookies that are categorized as "Necessary" are stored on your browser as they are essential for enabling the basic functionalities of the site. ... 

Always Active

Necessary cookies are required to enable the basic features of this site, such as providing secure log-in or adjusting your consent preferences. These cookies do not store any personally identifiable data.

Functional cookies help perform certain functionalities like sharing the content of the website on social media platforms, collecting feedback, and other third-party features.

Analytical cookies are used to understand how visitors interact with the website. These cookies help provide information on metrics such as the number of visitors, bounce rate, traffic source, etc.

Performance cookies are used to understand and analyze the key performance indexes of the website which helps in delivering a better user experience for the visitors.

Advertisement cookies are used to provide visitors with customized advertisements based on the pages you visited previously and to analyze the effectiveness of the ad campaigns.

Knowledge Hub

Pneumonia vaccines have large health and financial benefits, especially benefiting the poorest households

A study looking at the impact of pneumococcal vaccine introduction and scaling up pneumonia treatment in Ethiopia found that 30-40% of all deaths averted by these interventions would be expected to occur in the poorest wealth quintile. The greatest resulting financial risk protection would also be concentrated among the bottom income quintile.

Full Citation:
Johannsen, K.A, Memirie, S.T., Pecenka, C. et al. 2015. Health gains and financial protection from pneumococcal vaccination and pneumonia treatment in Ethiopia: Results from an extended cost-effectiveness analysis. PLOS ONE. 10(12).

Title of Article: Health gains and financial protection from pneumococcal vaccination and pneumonia treatment in Ethiopia: Results from an extended cost-effectiveness analysis

Author(s): Johannsen, K.A, Memirie, S.T., Pecenka, C. et al

Publication Year: 2015

Publication Name: PLOS ONE

Publication Volume: 10(12)

Publication Source URL: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4674114/

DOI (Digital Object Identifier): 10.1371/journal.pone.0142691

Topics: Equity

Disease Vaccines: Pneumococcal disease/PCV/PPSV | Pneumonia

Countries: Ethiopia

WHO Regions: Africa